Man Group’s Adverum Biotechnologies ADVM Stock Holding History

Man Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Hold	0	–	–	–	1862
2021 Q4	–	Sell	-6,559	Closed	-$142K	–	1931
2021 Q3	$142K	Sell	6,559 -6,340	-49%	-$162K	﹤0.01%	1791
2021 Q2	$451K	Buy	12,899 +7,969	+162%	+$429K	﹤0.01%	1588
2021 Q1	$486K	Sell	4,930 -8,712	-64%	-$1.05M	﹤0.01%	1485
2020 Q4	$1.48M	Sell	13,642 -670	-5%	-$82.9K	0.01%	1296
2020 Q3	$1.47M	Buy	+14,312	New	+$2.14M	0.01%	1284
2019 Q2	–	Sell	-3,851	Closed	-$202K	–	1870
2019 Q1	$202K	Sell	3,851 -50,438	-93%	-$2.04M	﹤0.01%	1879
2018 Q4	$1.71M	Sell	54,289 -2,000	-4%	-$81.4K	0.01%	1278
2018 Q3	$3.41M	Sell	56,289 -33,236	-37%	-$1.87M	0.01%	1198
2018 Q2	$4.75M	Sell	89,525 -41,080	-31%	-$2.47M	0.02%	978
2018 Q1	$7.58M	Buy	+130,605	New	+$8.13M	0.03%	618

Other funds holding ADVM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Man Group's ADVM Position: Q3 2023 in Review

Man Group held its Adverum Biotechnologies (ADVM) position steady in Q3 2023 at 0 shares worth $52.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

Man Group first reported a position in ADVM in Q1 2018 and has held it in 10 quarters since. The position peaked at $7.58M in Q1 2018. 59 funds tracked by Wall St. Rank hold ADVM as of Q3 2023.

Man Group held 0 shares of Adverum Biotechnologies worth $52.6K as of Q3 2023.
Man Group left its Adverum Biotechnologies share count unchanged in Q3 2023.
Adverum Biotechnologies made up ﹤0.01% of Man Group's portfolio in Q3 2023, its #1862 holding.
Man Group first reported a position in Adverum Biotechnologies in Q1 2018 and has held it in 10 quarters since.
Man Group's Adverum Biotechnologies position peaked at $7.58M in Q1 2018.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.